Our Collaborators

In August 2018, SpringWorks Therapeutics and BeiGene, Ltd. entered into a global clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of combining BeiGene’s investigational RAF dimer inhibitor, lifirafenib (BGB-283) with SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, in a range of genetically-defined solid tumors. The companies are preparing to initiate a Phase 1b clinical trial in patients with advanced solid tumors that harbor mutations in RAS, RAF, and other MAPK pathway genes.